Difference between revisions of "Team:Virgina/Safety"

Line 2: Line 2:
 
<html>
 
<html>
 
<head>
 
<head>
 +
<title>Modeling - U.Va. iGEM</title>
 
<!-- Bootstrap import -- Latest compiled and minified CSS -->
 
<!-- Bootstrap import -- Latest compiled and minified CSS -->
 
<link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.4/css/bootstrap.min.css" type="text/css">
 
<link rel="stylesheet" href="https://maxcdn.bootstrapcdn.com/bootstrap/3.3.4/css/bootstrap.min.css" type="text/css">
Line 38: Line 39:
  
 
<!-- OTHER STRUCTURAL CODE GOES BELOW HERE -->
 
<!-- OTHER STRUCTURAL CODE GOES BELOW HERE -->
<h2> Safety</h2>
 
<p>This goal of this project is to design a bacterial chassis that, when inserted into the human
 
  
digestive system, possess the capacity to moderate post-prandial glycemic spikes via the  
+
<div id="body-wrapper">
 +
<h1>Modeling</h1>
 +
 +
 +
<p>Modeling is a major component of our project since in the scope of this project, the direct effect of the transformed <i>E. coli</i> strain on reducing glycemic spikes cannot be tested in animal models, e.g. Rattus norvegicus. Instead, we will model the theoretical decrease in blood sugar levels based on data obtained from experiments that are performed in liquid solutions containing various concentrations of glucose and/or fructose. Thus, our first modeling goal is to predict the usefulness of our system and guide our experimental design, troubleshooting and future potential improvements.  In addition, since our project is related to health and would need to be orally taken to be effective, safety concerns should also be counted for. Thus, our second modeling goal is to show the degree of possible horizontal gene transfer between our modified <i>E. coli</i>  and endogenous gut flora.</p>
 +
 +
<h3>First Part: Modeling the efficacy of our design</h3>
 +
 +
<h4>Uptake of the sugar by the transformed strain</h4>
 +
<p>The uptake of the sugar is the cornerstone of the design. It is modeled as a function of promoter strength and concentration of free sugars. Thus we can find the range of uptake that is most physiologically reasonable and back-calculate the strength of the promoter to achieve the desired level of sugar uptake. Since the relative strength of the promoter family J23100 (Anderson, 2006) has been characterized, we could determine which promoter from the family is optimal based on our model. The model is made to fit data obtained from characterization process.</p>
 +
<!--[Picture/Table to come]-->
 +
<h4>Modeling of the glgC and sacB function</h4>
 +
<p>Conversion of simple sugars into complex saccharides is modeled as a function of simple sugar concentrations and expression level of the enzymes, glgC and sacB. The concentration profile of complex sugars is modeled as a function of free sugar concentrations inside cells, expression level of the genes and time. The cell death and release of the sugars will relate to concentration profile of complex sugars. The model will be used to estimate the input, the released complex sugars, for the model of reabsorption.</p><p>
  
absorption and polymerization of free floating simple sugars. In order for this to be a viable
+
Glycogen concentration is measured by absorbance. Because the recommended wavelength by
  
product for human consumption, a variety of safety measures must be considered and
+
the assay kit manufacturer is 570. Based on wavelength/absorbance plot provided by the
  
implemented to ensure that the product is incapable of harming the host. These factors include,  
+
manufacturer, we determined that the out of the wavelength filters that we have, the 540 nm is
  
but are not limited to: the biosafety level of the both the chassis and its transfected genes, the
+
most ideal. So we used the absorbance measured at 540 nm to reproduce a plot.
  
potential impact on blood glucose levels, and the removal and elimination of the product.</p>
+
</p>
 +
<a href="/wiki/images/4/4e/Virginia_glgCAssays.pdf" download><h5>Download the Assay Data Here</h5></a>
  
<h4>Biosafety </h4>
+
<!--[Picture/Table to come]-->
 +
<h4>Reabsorption of complex saccharides by the human body</h4>
 +
<p>Previous study has suggested that high molecular weight levan is digested into low molecular weight product and free fructose by gastric juice but not pancreatic enzymes (Yamamoto et al., 1999). Thus once inside the small intestine, the levan will not be digested and will reach the colon and be excreted out of the human body. Thus we only need to model the digestion and absorption of glycogen. Recently, a physiological model of intestinal absorption of glucose has been developed, and specifically the Ra has been estimated as a function of the amount of glucose in the gut (Man, Camilleri, & Cobelli, 2006):</p>
  
<p>Due to the invasive nature of this project, the safety level of the organism being inserted,
+
<!--
  
as well as its transfected genes, must be analyzed. The chassis used for this experiment is a strain
 
  
of E. coli known as K12. K12 E. coli is a Biosafety Level 1 organism, therefore it is not known
+
 +
 +
-->
 +
<p>Because the enzyme responsible for the breakdown of polysaccharides, pancreatic alpha-amylase (AMY2A), has been well-characterized (Narimasa, Tatsuo, Mitsutaka, & Toshio, 1979), we can use  Equation 2 (Butterworth, Warren, & Ellis, 2011) to estimate the amount of glucose from the amount of glycogen.</p>
 +
<!--
  
to cause disease in humans and presents a low risk to individuals working with it. In order for the
 
  
bacterial chassis to moderate levels of blood glucose, the gene EIIA (BBa_K1508002) was used
+
-->
 +
<p>The total amount (mass) of glucose can be assumed to equal the total amount of glycogen when all glycogen is depleted. Then, we can model the function of our transformed strain inside small intestine as a three-step linear process, where the free sugars are first taken by the bacteria, then polymerized inside the bacteria and then released after about 2 hours. The Ra will be compared with the Ra estimated without our device to quantify the effectiveness of our device to delay and reduce PPG level. Additionally, we can constrain our model to achieve an ideal Ra and solve for the parameters such as promoter strength of the two devices.</p>
 +
 +
 +
 +
<h3>Second Part: Modeling the rate of horizontal gene transfer</h3>
 +
<p>Horizontal gene transfer between our modified <i>E. coli</i>  and indigenous gut flora is something we must address as a safety concern. The most rapid means of horizontal gene transfer in bacteria is through the shuttle of plasmids. Transfer of plasmids occurs at about 1*10^-9 (ml cell^-1 h^-1, ref). And the number of <i>E. coli</i>  is decreasing (as determined by the growth assay). Thus the total number of transferred plasmid within one load could be modeled as an ODE. The number is calculated to be #, given the SacB could kill #% of the cells after 2 hrs.</p>
 +
 +
<p>Ideally, we could transform our modified <i>E. coli</i>  with a circuit composed of a consensus <i>E. coli</i>  promoter, GFP, a consensus ASF 361 promoter and RFP. If we measure the expression level of  GFP and RFP in the <i>E. coli</i>  and ASF 361 respectively and get distinct FU readings, we could use a flow cytofluorometer to find out the specific plasmid transfer rate of our modified <i>E. coli</i>  to a representative of the indigenous gut flora. However, we did not have the time to complete this experiment. </p>
  
in one of the two biobricks assembled for this project. EIIA is a Biosafety Level 1 gene that
 
  
codes for the increased uptake of glucose. Two additional genes inserted into the K12 chassis are
+
 
+
<style type="text/css">
glgC (BBa_K118017) and sacB (BBa_K322921). glgC functions to polymerize glucose into
+
#body-wrapper h1 {
 
+
color: black;
glycogen, while sacB functions to polymerize fructose into levan. Overall, the chassis and the
+
font-size: 40px;
 
+
text-align: center;
genes transfected into it separately confer a biosafety level of 1 for this project. </p>
+
font-family: Arial;
 
+
border: 0px;
<h4>Blood Glucose Levels </h4>
+
text-decoration: none;
 
+
font-weight: bold;
<p>As previously stated, the goal of this project is to mitigate glycemic spikes through the
+
}
 
+
#body-wrapper p {
absorption of excess glucose. Assays performed on glgC indicate that K12 cells expressing this
+
color:black;
 
+
}
gene polymerize high levels of glucose. This means that the presence of these cells in the
+
#body-wrapper {
 
+
width: 90%;
intestinal lumen will theoretically lower the amounts of free sugars that are able to be absorbed
+
margin-left:5%;
 
+
height: auto;
by the intestine. Currently, more experimentation is needed before we are able to analyze the
+
background: #fff;
 
+
border-radius: 20px;
effect of our chassis in vivo. However, because we have demonstrated that our modified K12
+
margin-top: 40px;
 
+
margin-bottom: 40px;
bacteria are able to carry out the conversion of glucose to glycogen, it is important to note that a
+
padding: 50px;
 
+
}
potential side effect to introducing this into the human digestive system is hypoglycemia.</p>
+
</style>
 
+
<h4>Removal and Elimination of the product <h4>
+
 
+
<p>In order for this product to function as a treatment for hyperglycemic spikes, the amount
+
 
+
of glucose absorbed as well as the duration of its functionality must be tightly regulated. 
+
 
+
Currently, our bacterial kill switch is the sacB gene. When exposed the fructose, this gene codes
+
 
+
for levan, which continues to build up until it reaches a toxic level, killing the cell. Fructose
+
 
+
assays performed on this gene indicate an inhibition of cell growth or lysis after two hours. This
+
 
+
means that in order to eliminate this product from the digestive system, it must be consumed
+
 
+
along with adequate levels of fructose to lyse the cells. A potential issue with this killswitch is
+
 
+
that, as of right now, we are unable to determine how it will behave in vivo. For example, if the
+
 
+
rate of fructose absorption through the intestine is much higher than the rate of absorption in the
+
 
+
bacterium, then it could take anywhere between a few hours to a few days before the levels of
+
 
+
intracellular levan is present at toxic levels in the bacteria.  Additionally, if a mutation occurred
+
 
+
that removed the functionality of sacB, there are no backup systems in place that would remove
+
 
+
the bacterium from the system. This would lead to a replicating colony of bacterium actively
+
 
+
competing for glucose in the gut. Depending on the functionality of these colonies in vivo, the
+
 
+
results could lead hypoglycemia and potential interactions with the microbial flora already
+
  
present in the digestive tract.</p>
+
</div>
  
 
<!-- SPECIFIC STRUCTURAL CODE ENDS HERE -->
 
<!-- SPECIFIC STRUCTURAL CODE ENDS HERE -->
Line 199: Line 190:
 
padding-top:5px;
 
padding-top:5px;
 
padding-bottom:5px;
 
padding-bottom:5px;
}
 
h2 {
 
color: white;
 
}
 
h4 {
 
color: white;
 
 
}
 
}
 
a:hover {
 
a:hover {
Line 236: Line 221:
 
font-family: Century Gothic, sans-serif;
 
font-family: Century Gothic, sans-serif;
 
}
 
}
footer {
+
footer {
 
width:100%
 
width:100%
 
height:300px;
 
height:300px;
Line 257: Line 242:
 
p {  
 
p {  
 
color:white;
 
color:white;
font-family: serif;
+
font-family: Arial;
 
float:center;
 
float:center;
 
clear:both;
 
clear:both;

Revision as of 14:23, 18 September 2015

Modeling - U.Va. iGEM

University of Virginia iGEM 2015

Modeling

Modeling is a major component of our project since in the scope of this project, the direct effect of the transformed E. coli strain on reducing glycemic spikes cannot be tested in animal models, e.g. Rattus norvegicus. Instead, we will model the theoretical decrease in blood sugar levels based on data obtained from experiments that are performed in liquid solutions containing various concentrations of glucose and/or fructose. Thus, our first modeling goal is to predict the usefulness of our system and guide our experimental design, troubleshooting and future potential improvements. In addition, since our project is related to health and would need to be orally taken to be effective, safety concerns should also be counted for. Thus, our second modeling goal is to show the degree of possible horizontal gene transfer between our modified E. coli and endogenous gut flora.

First Part: Modeling the efficacy of our design

Uptake of the sugar by the transformed strain

The uptake of the sugar is the cornerstone of the design. It is modeled as a function of promoter strength and concentration of free sugars. Thus we can find the range of uptake that is most physiologically reasonable and back-calculate the strength of the promoter to achieve the desired level of sugar uptake. Since the relative strength of the promoter family J23100 (Anderson, 2006) has been characterized, we could determine which promoter from the family is optimal based on our model. The model is made to fit data obtained from characterization process.

Modeling of the glgC and sacB function

Conversion of simple sugars into complex saccharides is modeled as a function of simple sugar concentrations and expression level of the enzymes, glgC and sacB. The concentration profile of complex sugars is modeled as a function of free sugar concentrations inside cells, expression level of the genes and time. The cell death and release of the sugars will relate to concentration profile of complex sugars. The model will be used to estimate the input, the released complex sugars, for the model of reabsorption.

Glycogen concentration is measured by absorbance. Because the recommended wavelength by the assay kit manufacturer is 570. Based on wavelength/absorbance plot provided by the manufacturer, we determined that the out of the wavelength filters that we have, the 540 nm is most ideal. So we used the absorbance measured at 540 nm to reproduce a plot.

Download the Assay Data Here

Reabsorption of complex saccharides by the human body

Previous study has suggested that high molecular weight levan is digested into low molecular weight product and free fructose by gastric juice but not pancreatic enzymes (Yamamoto et al., 1999). Thus once inside the small intestine, the levan will not be digested and will reach the colon and be excreted out of the human body. Thus we only need to model the digestion and absorption of glycogen. Recently, a physiological model of intestinal absorption of glucose has been developed, and specifically the Ra has been estimated as a function of the amount of glucose in the gut (Man, Camilleri, & Cobelli, 2006):

Because the enzyme responsible for the breakdown of polysaccharides, pancreatic alpha-amylase (AMY2A), has been well-characterized (Narimasa, Tatsuo, Mitsutaka, & Toshio, 1979), we can use Equation 2 (Butterworth, Warren, & Ellis, 2011) to estimate the amount of glucose from the amount of glycogen.

The total amount (mass) of glucose can be assumed to equal the total amount of glycogen when all glycogen is depleted. Then, we can model the function of our transformed strain inside small intestine as a three-step linear process, where the free sugars are first taken by the bacteria, then polymerized inside the bacteria and then released after about 2 hours. The Ra will be compared with the Ra estimated without our device to quantify the effectiveness of our device to delay and reduce PPG level. Additionally, we can constrain our model to achieve an ideal Ra and solve for the parameters such as promoter strength of the two devices.

Second Part: Modeling the rate of horizontal gene transfer

Horizontal gene transfer between our modified E. coli and indigenous gut flora is something we must address as a safety concern. The most rapid means of horizontal gene transfer in bacteria is through the shuttle of plasmids. Transfer of plasmids occurs at about 1*10^-9 (ml cell^-1 h^-1, ref). And the number of E. coli is decreasing (as determined by the growth assay). Thus the total number of transferred plasmid within one load could be modeled as an ODE. The number is calculated to be #, given the SacB could kill #% of the cells after 2 hrs.

Ideally, we could transform our modified E. coli with a circuit composed of a consensus E. coli promoter, GFP, a consensus ASF 361 promoter and RFP. If we measure the expression level of GFP and RFP in the E. coli and ASF 361 respectively and get distinct FU readings, we could use a flow cytofluorometer to find out the specific plasmid transfer rate of our modified E. coli to a representative of the indigenous gut flora. However, we did not have the time to complete this experiment.

University of Virginia iGEM

148 Gilmer Hall

485 McCormick Road

Charlottesville, Virginia 22904

United States of America

virginia.igem@gmail.com